109
Participants
Start Date
May 7, 2021
Primary Completion Date
December 31, 2024
Study Completion Date
June 30, 2026
KRT-232
KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
Dasatinib
Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
Nilotinib
Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
RECRUITING
APHM Hopital de la Timone, Marseille
RECRUITING
Institut Paoli-Calmettes, Marseille
RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
RECRUITING
Fondazione IRCCS Policlinico San Matteo, Pavia
RECRUITING
Clínica Universidad de Navarra, Madrid
RECRUITING
Hospital Universitario La Paz, Madrid
RECRUITING
Georgia Cancer Center at Augusta University, Augusta
RECRUITING
Clinica Universidad de Navarra, Pamplona
RECRUITING
University of Alabama Birmingham, Birmingham
RECRUITING
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola FC
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
Centre Leon Berard, Lyon
RECRUITING
Centre Hospitalier Lyon Sud, Saint-Genis-Laval
RECRUITING
Texas Oncology- Sammons CC at Baylor, Dallas
RECRUITING
Azienda Ospedaliero - Universitaria Mater Domini, Catanzaro
RECRUITING
National Medical Research Center of Hematology, Moscow
RECRUITING
Almazov National Medical Research Center, Saint Petersburg
RECRUITING
Samara State Medical University, Samara
RECRUITING
Princess Margaret Cancer Center, Toronto
RECRUITING
"Policlinico di Milano Ospedale Maggiore , Fondazione IRCCS Ca' Granda"
RECRUITING
Pratia Onkologia Katowice, Katowice
RECRUITING
Kyungpook National University Hospital, Daegu
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Severance Hospital, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Hospital Universitari Vall d'Hebron, Barcelona
Lead Sponsor
Kartos Therapeutics, Inc.
INDUSTRY